Cassava Sciences (id:5282 SAVA)
26.48 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 10:42:41 AM)
Exchange closed, opens in 1 day 22 hours
About Cassava Sciences
Market Capitalization 1.34B
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
| Headquarters (address) |
6801 N. Capital of Texas Highway Austin 78731 TX United States |
| Phone | 512 501 2444 |
| Website | https://www.cassavasciences.com |
| Employees | 29 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | SAVA |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 8.79 - 42.20 |
| Market Capitalization | 1.34B |
| Dividend yield forward | 79.31 % |
| Dividend yield forward United States (ID:6, base:1866) | 4.15 % |
| P/E trailing | -11.41 |
| P/E forward | -15.79 |
| Price/Book | 8.05 |
| Beta | -0.583 |
| EPS | -1.38 |
| EPS United States (ID:6, base:3400) | 24.26 |
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Cassava Sciences has raised their dividend 79.31 years in a row. This is below the 41189.371300 year average in the 'Biotechnology' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Cassava Sciences has raised their dividend 79.31 years in a row. This is below the 41189.371300 year average in the 'Biotechnology' industry